CN114901270A - 治疗自闭症谱系障碍的症状的方法 - Google Patents

治疗自闭症谱系障碍的症状的方法 Download PDF

Info

Publication number
CN114901270A
CN114901270A CN202080087440.9A CN202080087440A CN114901270A CN 114901270 A CN114901270 A CN 114901270A CN 202080087440 A CN202080087440 A CN 202080087440A CN 114901270 A CN114901270 A CN 114901270A
Authority
CN
China
Prior art keywords
treatment
patient
points
score
asd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080087440.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·伍德
J·莉莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Map Light Therapy Co Ltd
Original Assignee
Map Light Therapy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Light Therapy Co Ltd filed Critical Map Light Therapy Co Ltd
Publication of CN114901270A publication Critical patent/CN114901270A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080087440.9A 2019-10-23 2020-10-23 治疗自闭症谱系障碍的症状的方法 Pending CN114901270A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925023P 2019-10-23 2019-10-23
US62/925,023 2019-10-23
US202063011715P 2020-04-17 2020-04-17
US63/011,715 2020-04-17
PCT/US2020/057133 WO2021081376A1 (en) 2019-10-23 2020-10-23 Methods of treating the symptoms of autism spectrum disorder

Publications (1)

Publication Number Publication Date
CN114901270A true CN114901270A (zh) 2022-08-12

Family

ID=75620321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080087440.9A Pending CN114901270A (zh) 2019-10-23 2020-10-23 治疗自闭症谱系障碍的症状的方法

Country Status (17)

Country Link
US (1) US20220387396A1 (https=)
EP (2) EP4681714A3 (https=)
JP (2) JP7766026B2 (https=)
KR (1) KR20220122602A (https=)
CN (1) CN114901270A (https=)
AU (1) AU2020370479A1 (https=)
CA (1) CA3158781A1 (https=)
DK (1) DK4048249T3 (https=)
ES (1) ES3056138T3 (https=)
FI (1) FI4048249T3 (https=)
HR (1) HRP20251489T1 (https=)
IL (1) IL292367B1 (https=)
LT (1) LT4048249T (https=)
MX (2) MX2022004910A (https=)
PT (1) PT4048249T (https=)
SI (1) SI4048249T1 (https=)
WO (1) WO2021081376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022079307A1 (en) * 2020-10-16 2022-04-21 Purposeful Ike Compositions and uses thereof
US20240189240A1 (en) * 2021-03-25 2024-06-13 Maplight Therapeutics, Inc. Pharmaceutical compositions comprising zolmitriptan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170081273A1 (en) * 2014-05-19 2017-03-23 Northeastern University Serotonin Receptor-Targeting Compounds and Methods
US20180028499A1 (en) * 2015-02-25 2018-02-01 The Regents Of The University Of California 5ht agonists for treating disorders
CN108243608A (zh) * 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236787B2 (en) * 2008-12-09 2012-08-07 Synthonics, Inc. Frequency modulated drug delivery (FMDD)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170081273A1 (en) * 2014-05-19 2017-03-23 Northeastern University Serotonin Receptor-Targeting Compounds and Methods
US20180028499A1 (en) * 2015-02-25 2018-02-01 The Regents Of The University Of California 5ht agonists for treating disorders
CN108243608A (zh) * 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIEGEL，等: "The autism inpatient collection:methods and preliminary sample description.", MOLECULAR AUTISM, vol. 6, no. 61, 10 November 2015 (2015-11-10), pages 1 - 10 *

Also Published As

Publication number Publication date
ES3056138T3 (en) 2026-02-18
WO2021081376A1 (en) 2021-04-29
KR20220122602A (ko) 2022-09-02
US20220387396A1 (en) 2022-12-08
EP4681714A3 (en) 2026-04-15
EP4048249A1 (en) 2022-08-31
IL292367B1 (en) 2026-04-01
HRP20251489T1 (hr) 2026-01-02
LT4048249T (lt) 2026-02-10
JP2026031955A (ja) 2026-02-25
DK4048249T3 (da) 2025-12-15
MX2022004910A (es) 2022-08-18
AU2020370479A1 (en) 2022-04-28
EP4681714A2 (en) 2026-01-21
JP7766026B2 (ja) 2025-11-07
PT4048249T (pt) 2025-12-02
EP4048249B1 (en) 2025-09-03
JP2022554090A (ja) 2022-12-28
EP4048249A4 (en) 2023-12-13
FI4048249T3 (fi) 2025-12-05
SI4048249T1 (sl) 2026-04-30
MX2025008168A (es) 2025-08-01
CA3158781A1 (en) 2021-04-29
IL292367A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2017229656B2 (en) Neuroactive steroids, compositions, and uses thereof
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
JP2021063136A (ja) 神経発達障害療法
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
US20220023316A1 (en) Methods for the treatment of depression
CN104394866A (zh) 用于治疗精神和行为病症的药物
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
EP3448379B1 (en) Treatment of impulsivity-related disorders
Toda et al. Administration of secretin for autism alters dopamine metabolism in the central nervous system
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
KR20240165982A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
KR20230107257A (ko) 심리적 고통의 치료를 위한 칸나비디올의 용도
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
HK40080588B (en) Methods of treating the symptoms of autism spectrum disorder
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
US20250041248A1 (en) Alz-801 for use in treating alzheimer&#39;s disease
CA3052796A1 (en) Treatment of asthma with cysteamine
Duncan et al. Antidepressants
HK40083948A (en) A2-73 for treating angelman syndrome, williams syndrome smith-magenis syndrome and multiple sclerosis
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination